Influence of Janus kinase inhibition on interleukin 6-mediated induction of acute-phase serum amyloid A in rheumatoid synovium

Journal of Rheumatology

Volumn 38, Issue 11, 2011, Pages 2309-2317

  Migita, Kiyoshi ^a   Koga, Tomohiro ^b   Komori, Atsumasa ^a   Torigoshi, Takafumi ^a   Maeda, Yumi ^a   Izumi, Yasumori ^a   Sato, Junji ^c   Jiuchi, Yuka ^a   Miyashita, Taiichiro ^a   Yamasaki, Satoshi ^b   Kawakami, Atsushi ^b   Nakamura, Minoru ^a   Motokawa, Satoru ^a   Ishibashi, Hiromi ^a  

^a NATIONAL HOSPITAL ORGANIZATION NAGASAKI MEDICAL CENTER   (Japan)

^b NAGASAKI UNIVERSITY HOSPITAL   (Japan)

^c EIKEN CHEMICAL CO LTD   (Japan)

Author keywords

AA amyloidosis; CP690,550; Janus kinase; Rheumatoid arthritis; Serum amyloid A; Signal transducers and activators of transcription

Indexed keywords

INTERLEUKIN 6; JANUS KINASE 1; JANUS KINASE 2; MESSENGER RNA; SERUM AMYLOID A; SERUM AMYLOID A1; SERUM AMYLOID A2; SERUM AMYLOID A4; STAT3 PROTEIN; TASOCITINIB; UNCLASSIFIED DRUG;

ACUTE PHASE SERUM AMYLOID A GENE; ARTICLE; CELL STIMULATION; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FIBROBLAST; GENE; GENE ACTIVATION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYNOVIOCYTE; SYNOVIUM; WESTERN BLOTTING;

ACUTE-PHASE REACTION; ARTHRITIS, RHEUMATOID; CELLS, CULTURED; ENZYME INHIBITORS; HUMANS; INTERLEUKIN-6; JANUS KINASE 2; JANUS KINASE 3; JANUS KINASES; PYRIMIDINES; PYRROLES; RNA, MESSENGER; SERUM AMYLOID A PROTEIN; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; SYNOVIAL MEMBRANE;

EID: 80155168933     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.101362     Document Type: Article

References (45)

1. Tak PP, Bresnihan B. The pathogenesis and prevention of joint damage in rheumatoid arthritis: advances from synovial biopsy and tissue analysis. Arthritis Rheum 2000;43:2619-33. (Pubitemid 32001727)
2. Wollheim FA. Markers of disease in rheumatoid arthritis. Curr Opin Rheumatol 2000;12:200-4. (Pubitemid 30238388)
3. Husby G, Husebekk A, Skogen B, Sletten K, Marhaug G, Magnus J, et al. Serum amyloid A (SAA) - the precursor of protein AA in secondary amyloidosis. Adv Exp Med Biol 1988;243:185-92.
4. O'Hara R, Murphy EP, Whitehead AS, FitzGerald O, Bresnihan B. Acute-phase serum amyloid A production by rheumatoid arthritis synovial tissue. Arthritis Res 2000;2:142-4.
5. Vallon R, Freuler F, Desta-Tsedu N, Robeva A, Dawson J, Wenner P, et al. Serum amyloid A (apoSAA) expression is up-regulated in rheumatoid arthritis and induces transcription of matrix metalloproteinases. J Immunol 2001;166:2801-7. (Pubitemid 32173521)
6. Cunnane G. Amyloid precursors and amyloidosis in inflammatory arthritis. Curr Opin Rheumatol 2001;13:67-73. (Pubitemid 32042795)
7. Connolly M, Marrelli A, Blades M, McCormick J, Maderna P, Godson C, et al. Acute serum amyloid A induces migration, angiogenesis, and inflammation in synovial cells in vitro and in a human rheumatoid arthritis/SCID mouse chimera model. J Immunol 2010;184:6427-37.
8. Koga T, Torigoshi T, Motokawa S, Miyashita T, Maeda Y, Nakamura M, et al. Serum amyloid A-induced IL-6 production by rheumatoid synoviocytes. FEBS Lett 2008;582:579-85.
9. Migita K, Kawabe Y, Tominaga M, Origuchi T, Aoyagi T, Eguchi K. Serum amyloid A protein induces production of matrix metalloproteinases by human synovial fibroblasts. Lab Invest 1998;78:535-9. (Pubitemid 28246977)
10. Uhlar CM, Whitehead AS. Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem 1999;265:501-23. (Pubitemid 29488982)
11. Meek RL, Urieli-Shoval S, Benditt EP. Expression of apolipoprotein serum amyloid A mRNA in human atherosclerotic lesions and cultured vascular cells: implications for serum amyloid A function. Proc Natl Acad Sci USA 1994;91:3186-90. (Pubitemid 24130200)
12. Jensen LE, Whitehead AS. Regulation of serum amyloid A protein expression during the acute-phase response. Biochem J 1998;334:489-503. (Pubitemid 28457193)
13. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996;14:397-440. (Pubitemid 26130190)
14. Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2004;50:1761-9. (Pubitemid 38725087)
15. Hagihara K, Nishikawa T, Isobe T, Song J, Sugamata Y, Yoshizaki K. IL-6 plays a critical role in the synergistic induction of human serum amyloid A (SAA) gene when stimulated with proinflammatory cytokines as analyzed with an SAA isoform real-time quantitative RT-PCR assay system. Biochem Biophys Res Commun 2004;314:363-9. (Pubitemid 38084725)
16. Kishimoto T, Akira S, Taga T. IL-6 receptor and mechanism of signal transduction. Int J Immunopharmacol 1992;14:431-8.
17. Hirano T, Ishihara K, Hibi M. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene 2000;19:2548-56. (Pubitemid 30339210)
18. Hagihara K, Nishikawa T, Sugamata Y, Song J, Isobe T, Taga T, et al. Essential role of STAT3 in cytokine-driven NF-kappa B-mediated serum amyloid A gene expression. Genes Cells 2005;10:1051-63. (Pubitemid 41556074)
19. Coombs JH, Bloom BJ, Breedveld FC, Fletcher MP, Gruben D, Kremer JM, et al. Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 2010;69:413-6.
20. Kremer JM, Bloom BJ, Breedveld FC, Coombs JH, Fletcher MP, Gruben D, et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum 2009;60:1895-905.
21. Ghoreschi K, Laurence A, O'Shea JJ. Selectivity and therapeutic inhibition of kinases: to be or not to be? Nat Immunol 2009;10:356-60.
22. Yamada T, Nomata Y, Sugita O, Okada M. A rapid method for measuring serum amyloid A protein by latex agglutination nephelometric immunoassay. Ann Clin Biochem 1993;30:72-6. (Pubitemid 23049423)
23. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24. (Pubitemid 18091653)
24. Kumon Y, Suehiro T, Hashimoto K, Nakatani K, Sipe JD. Local expression of acute phase serum amyloid A mRNA in rheumatoid arthritis synovial tissue and cells. J Rheumatol 1999;26:785-90. (Pubitemid 29195663)
25. Hintzen C, Quaiser S, Pap T, Heinrich PC, Hermanns HM. Induction of CCL13 expression in synovial fibroblasts highlights a significant role of oncostatin M in rheumatoid arthritis. Arthritis Rheum 2009;60:1932-43.
26. Malle E, De Beer FC. Human serum amyloid A (SAA) protein: a prominent acute-phase reactant for clinical practice. Eur J Clin Invest 1996;26:427-35. (Pubitemid 26226404)
27. Cunnane G, Whitehead AS. Amyloid precursors and amyloidosis in rheumatoid arthritis. Baillieres Best Pract Res Clin Rheumatol 1999;13:615-28. (Pubitemid 30050431)
28. Migita K, Koga T, Torigoshi T, Maeda Y, Miyashita T, Izumi Y, et al. Serum amyloid A protein stimulates CCL20 production in rheumatoid synoviocytes. Rheumatology 2009;48:741-7.
29. Marhaug G, Dowton SB. Serum amyloid A: an acute phase apolipoprotein and precursor of AA amyloid. Baillieres Clin Rheumatol 1994;8:553-73. (Pubitemid 24256891)
30. Heinrich PC, Behrmann I, Müller-Newen G, Schaper F, Graeve L. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J 1998;334:297-314. (Pubitemid 28448572)
31. Kishimoto T. Interleukin-6: from basic science to medicine - 40 years in immunology. Annu Rev Immunol 2005;23:1-21. (Pubitemid 40563163)
32. Ishihara K, Hirano T. IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev 2002;13:357-68.
33. Timmer TC, Baltus B, Vondenhoff M, Huizinga TW, Tak PP, Verweij CL, et al. Inflammation and ectopic lymphoid structures in rheumatoid arthritis synovial tissues dissected by genomics technology: identification of the interleukin-7 signaling pathway in tissues with lymphoid neogenesis. Arthritis Rheum 2007;56:2492-502. (Pubitemid 47237268)
34. Changelian PS, Flanagan ME, Ball DJ, Kent CR, Magnuson KS, Martin WH, et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 2003;302:875-8. (Pubitemid 37339629)
35. Williams NK, Bamert RS, Patel O, Wang C, Walden PM, Wilks AF, et al. Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains. J Mol Biol 2009;387:219-32.
36. Jiang JK, Ghoreschi K, Deflorian F, Chen Z, Perreira M, Pesu M, et al. Examining the chirality, conformation and selective kinase inhibition of 3-((3R,4R)-4-methyl-3-(methyl (7H-pyrrolo[2,3-d] pyrimidin-4-yl)amino)piperidin- 1-yl)-3-oxopropanenitrile (CP-690,550). J Med Chem 2008;51:8012-8.
37. Walker JG, Ahern MJ, Coleman M, Weedon H, Papangelis V, Beroukas D, et al. Expression of Jak3, STAT1, STAT4, and STAT6 in inflammatory arthritis: unique Jak3 and STAT4 expression in dendritic cells in seropositive rheumatoid arthritis. Ann Rheum Dis 2006;65:149-56. (Pubitemid 43131986)
38. Pietrangelo A, Dierssen U, Valli L, Garuti C, Rump A, Corradini E, et al. STAT3 is required for IL-6-gp130-dependent activation of hepcidin in vivo. Gastroenterology 2007;132:294-300. (Pubitemid 46108739)
39. Uhlar CM, Whitehead AS. Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem 1999;265:501-23. (Pubitemid 29488982)
40. Gottenberg JE, Merle-Vincent F, Bentaberry F, Allanore Y, Berenbaum F, Fautrel B, et al. Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy. Arthritis Rheum 2003;48:2019-24. (Pubitemid 36828697)
41. Tanaka N, Yonekura H, Yamagishi S, Fujimori H, Yamamoto Y, Yamamoto H. The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa B, and by 17 beta-estradiol through Sp-1 in human vascular endothelial cells. J Biol Chem 2000;275:25781-90.
42. Gillmore JD, Lovat LB, Persey MR, Pepys MB, Hawkins PN. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 2001;358:24-9. (Pubitemid 32709735)
43. Lachmann HJ, Goodman HJ, Gilbertson JA, Gallimore JR, Sabin CA, Gillmore JD, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med 2007;356:2361-71. (Pubitemid 46883770)
44. Okuda Y, Takasugi K. Successful use of a humanized anti-interleukin-6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis. Arthritis Rheum 2006;54:2997-3000. (Pubitemid 44497781)
45. O'Hara R, Murphy EP, Whitehead AS, FitzGerald O, Bresnihan B. Local expression of the serum amyloid A and formyl peptide receptor-like 1 genes in synovial tissue is associated with matrix metalloproteinase production in patients with inflammatory arthritis. Arthritis Rheum 2004;50:1788-99. (Pubitemid 38725091)